Patent Overview of Bosulif's Manufacturing Process
Bosulif, an oral tyrosine kinase inhibitor developed by Pfizer, is used to treat adults with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The manufacturing process for Bosulif involves complex chemical synthesis [1] and particle engineering techniques.
Process Patents
US Patent No. 8,557,444, filed on November 2, 2007, and issued on October 29, 2013, discloses a crystalline form of bosutinib and processes for its preparation. The patent covers methods for isolating and purifying bosutinib using recrystallization techniques [2].
Additionally, US Patent No. 9,245,778, filed on November 15, 2013, and issued on January 26, 2016, claims a process for crystallizing bosutinib from a solution using a seeding step [3].
Manufacturing Process Patents Expiration
The patents that cover the manufacturing process for Bosulif will expire as follows:
- US Patent No. 8,557,444 expires on October 29, 2033.
- US Patent No. 9,245,778 expires on January 26, 2037.
Patent Expiration and Competition
After the patents expire, other pharmaceutical companies will be able to develop generic versions of Bosulif's manufacturing process, potentially increasing competition in the market and lowering prices for patients. However, manufacturers may still be restricted by other patents related to Bosulif's active pharmaceutical ingredient.
Sources
[1] https://www.drugpatentwatch.com/ - A comprehensive database of patented pharmaceutical compounds, including Bosulif (Bosutinib).
[2] US Patent 8,557,444 - Bosutinib - Crystal Form and Preparation Methods (issued October 29, 2013).
[3] US Patent 9,245,778 - Bosutinib - Crystallization Process (issued January 26, 2016).
[4] DrugPatentWatch.com - Bosutinib (Bosulif), a tyrosine kinase inhibitor for leukemia treatment.